CROI 2016 Program at a Glance

Keyword Index

Postpartum - 623, 791 Posttreatment control - 87, 347, 352, 358LB Pre-ART - 346, 477 Preexposure prophylaxis (PrEP) – 15, 48LB, 68, 69, 70, 71, 96, 103, 105, 106, 107, 109LB, 301, 333, 448, 471, 478, 521, 522, 524, 567, 479LB, 866, 868, 869, 870, 877, 878, 879, 881, 882LB, 883LB, 884, 885, 886, 887, 888, 889, 890, 891, 892, 894, 1051, 1052, 1055, 1056, 1057 Pregnancy - 49, 433, 438, 439, 757, 770, 771, 772, 774, 775, 776, 791, 792, 794, 795, 798, 799, 804, 811, 862 Prematurity - 799, 803 Preterm - 798, 803 Prevalence - 64, 483, 829, 860, 903, 905, 928 Prevention - 4, 5, 79, 101, 103, 108LB, 844, 861, 870, 894, 934, 1025 Prevention for Positives - 989, 997 Prevention of mother-to-child transmission (PMTCT) - 34, 119, 433, 438, 441, 776, 777, 778, 790, 795, 805 · and option B plus – 35LB, 757, 782 Primary health care - 79, 585, 788, 1035 Primary HIV infection - 142, 218 Primary HIV-1 infection - 237, 522, 729 Probiotics - 238, 263 Program effectiveness - 163, 782 Progression of HAND - 381 Prophylaxis - 37, 768 Prospective observational study - 762, 942 Protease - 319 • Cleavage sites - 319 • Inhibitor - 498, 776, 1030 • Inhibitor cross-resistance - 464 • Inhibitor mutation - 427 Protein-protein interaction - 202 Proteome - 208 Proteomics - 6, 279 Provider education - 892 Proximal tubule – 691, 868 PTH - 700 Puberty - 852 Pulmonary tuberculosis – 158LB, 733, 736, 764, 995 Pulse wave velocity - 658 Purinergic - 249 Pyroptosis - 240, 295 –Q– Q-VOA - 341 Q80K - 543 Quality of care (QoC) - 994, 1035 Quality of life - 475

Quasispecies - 149 –R– Racial disparities - 43, 476, 531, 700 RAD51 - 246 Radiotherapy - 620 Raltegravir - 30, 508, 953 Randomized clinical trial - 109LB, 424LB Randomized controlled trial - 27, 28, 41, 113LB, 470, 747, 790 Randomized double-blind placebo- controlled trial – 79LB, 103, 419, 681, 682, 875 Randomized trial - 475, 621, 980 Rapid diagnostic tests - 519, 522, 968 Rapid Pathway - 1017 Ravidasvir - 153 Re-engagement in Care - 27, 992 Reactivation - 369 Reactive oxygen species (ROS) - 282 Real-time PCR - 812 Rebound virus - 92 Recency of HIV Infection – 485, 515 Recombinants - 210, 213, 806 Record linkage - 613 Recreational substance use - 1034 Rectal microbicides – 108LB, 880, 882LB Rectal tissue - 102LB Regression discontinuity – 960, 1011, 1012, 1048 RegulatoryT cells - 242 Reinfection - 533 Relapse - 573, 588, 601 Renal • Function - 684, 866, 867 • Function impairment - 153, 426, 682, 857 • Toxicity - 452, 683 Repertoire - 179 Replication - 189 Replication-competent virus - 82 Replication-competent reservoir - 336 Research data integrity - 1053 Reservoir – 85, 258LB, 332, 353, 807 Resistance - 434, 491LB, 575, 849, 940, 1029 Resistance associated variants - 577, 580 Resource Limited Setting - 30, 493LB, 731, 787, 844, 899, 845, 907, 957, 960, 1013, 1031, 1027 Respondent-driven sampling - 898 Resting state fMRI - 390, 392 • Tubular disease - 426, 683 Repeat testing - 900, 977, 979 Resistance mutation – 490, 506 Resistance testing – 493LB, 497

Restriction factor - 57, 136, 199, 200 Retention - 34, 789, 1011 Retention in care - 116, 121, 790, 792, 844, 996, 1010, 1015, 1021, 1022, 1035, 1040 Return to care - 992, 1021 Reverse transcription - 468 Rhesus macaque - 84, 105, 268, 272, 273 Ribavirin - 99, 573 Rif and INH Resistance - 749 Rifabutin - 456, 753 Rifampicin - 459, 754 Rilpivirine – 31LB, 71, 453, 874, 945 Risk behavior - 260, 770, 932 Risk factor analysis - 215, 670, 913, 951 Risk factors - 54, 55, 171, 630, 744, 833, 916, 936, 1046 Risky sexual behavior - 898, 913, 973 Ritonavir - 459 Ritonavir-boosted lopinavir - 851 RNA seq - 807, 880 RNA splicing - 192 Romidepsin - 26LB Rosuvastatin - 674 Rural - 676, 965 RV144 - 317 RyanWhite - 1001, 1002 –S– Safety - 116, 461LB, 810, 818, 1120 Safety - 461LB Salicylate - 463 SAMHD1 - 205, 207, 468 sCD14 - 239 sCD163 - 690 Screening - 156, 531, 532, 565, 622, 648, 740, 869, 966, 1005 Second-line AntiretroviralTherapy - 498, 666, 752, 850, 1030 Self-report - 704, 907, 954 Self-reported condom use - 865 Semen – 75LB, 164, 268, 285, 351, 730 Semen biological marker - 864 Seminal shedding - 727 Senescence - 183 Sensitive testing - 519 Sequaela - 73LB Sequencing - 201, 219 Sequential Envs - 806 Serious adverse events - 962 Serious Non-AIDS Events - 559, 711 Seroconversion - 519, 894 Seroconverters - 519, 569 Serodiscordant couples - 167, 200, 301, 1063 Serology - 72LB

Keyword Index

CROI 2016 173